Lv4
480 积分 2026-04-10 加入
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
1天前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
1个月前
已完结
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
1个月前
已完结